Repeated administration of DY-9836 attenuated BCAS-induced learning and cognitive impairment. It restored the phosphorylated CaMK-II in hippocampal CA1 neurons and reduced inflammation by inhibiting the NLRP3/Caspase-1/IL-1β signaling pathway. Here, NLRP3 is linked to Cognitive impairment.